(Reuters) – Pfizer said on Monday its respiratory syncytial virus (RSV) vaccine Abrysvo generated a strong immune response in a late-stage study of four groups of adults aged 18 and older with a compromised immune system. Furthermore, the study highlights how the RSV vaccine benefits extend beyond just preventing infection. #RSVVaccineBenefits
Pfizer reported that a single 120 microgram dose of the vaccine generated strong neutralizing antibodies against RSV-A and RSV-B. This effect was observed across all groups in the study.
Abrysvo was well-tolerated in the study and showed a safety profile consistent with findings from other studies of the vaccine, it added.
The drugmaker plans to submit the data to regulatory agencies for review.
The study tested two doses of Abrysvo in 203 adults with compromised immunity. Participants included those with lung cancer, end-stage kidney disease, autoimmune disorders, and organ transplants. All groups were at risk of severe RSV-associated disease.
Pfizer’s vaccine is currently approved for people aged 60 and older and for use in women during the middle of the third trimester of pregnancy to protect their babies.
RSV usually causes cold-like symptoms but can lead to severe pneumonia in toddlers and older adults. Annually, it results in 177,000 hospitalizations and 14,000 deaths in the United States.
Moreover, these findings underscore the importance of continuing to evaluate and promote RSV vaccine benefits. Health authorities should consider these results when recommending vaccines to immuno-compromised adults. By doing so, they can enhance the quality of life for these individuals and reduce RSV-related health burdens. #RSVVaccineBenefits
read more
